These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 17560868)

  • 1. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
    Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
    Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
    White WB; Pitt B; Preston RA; Hanes V
    Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
    Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
    J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of 17beta-estradiol over 3 months without progestin co-administration does not improve coronary flow reserve in post-menopausal women: a randomized placebo-controlled cross-over CMR study.
    Schwitter J; Kozerke S; Bremerich J; Baltes C; Attenhofer Jost C; Birkhäuser M; Boesiger P; Buser P
    J Cardiovasc Magn Reson; 2007; 9(4):665-72. PubMed ID: 17578722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
    Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
    Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of drospirenone/estrogen combinations on bone metabolism.
    Christiansen C
    Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
    Tankó LB; Christiansen C
    J Intern Med; 2005 Dec; 258(6):544-53. PubMed ID: 16313478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
    Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
    Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
    Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drospirenone and estradiol: a new option for the postmenopausal woman.
    Archer DF
    Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram.
    Kawano H; Nagayoshi Y; Soejima H; Tanaka Y; Hokamaki J; Miyamoto S; Miyazaki Y; Yamabe H; Ogawa H
    Menopause; 2008; 15(2):352-6. PubMed ID: 18090872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study.
    Caruso S; Serra A; Grillo C; Maiolino L; Agnello C; Di Mari L; Cianci A
    Menopause; 2008; 15(5):963-6. PubMed ID: 18391834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
    Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
    Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.